CARTOX (hERG Toxicity Assay)
At Greenstone Biosciences, we recognize that cardiotoxicity is one of the most common reasons for drug failure, both in development and after market approval. Traditional preclinical models often fall short in predicting adverse cardiac effects, especially those involving the hERG (human Ether-à-go-go-Related Gene) potassium channel, a critical regulator of cardiac rhythm.
Our CARTOX platform provides a powerful, human-relevant solution by assessing drug candidates for hERG channel inhibition and arrhythmia risk using iPSC-derived cardiomyocytes. These patient-specific cardiac cells recapitulate the electrical activity of the human heart, enabling us to detect early warning signals of potential cardiotoxicity with high fidelity.
What CARTOX Delivers
De-Risking Development
By integrating cutting-edge electrophysiology with human iPSC-derived cardiomyocytes, CARTOX offers a reliable readout of cardiac safety liabilities long before costly clinical trials begin. This approach helps de-risk drug development pipelines, supports regulatory submissions, and ensures that only the safest candidates advance.
Shaping the Future of Cardiac Safety
CARTOX not only prevents the advancement of unsafe compounds but also enables more confident go/no-go decisions, accelerates timelines, and provides researchers with actionable data to optimize compounds early in development. With CARTOX, cardiac safety is no longer a late-stage hurdle—it becomes an integral part of the discovery process.
Start hERG Toxicity Screening
Confidently advance safer compounds using CARTOX’s human-relevant cardiac models.